Acta Materia Medica (@AMM_journal) header
Acta Materia Medica (@AMM_journal) profile picture

An open platform for rapid publication of the latest pharmaceutical science research. Bluesky - https://teapawt.net/t.co/rkG5gUqXjz

Shannon, Ireland
Joined November 2021
Photo by Acta Materia Medica (@AMM_journal)Photo by Acta Materia Medica (@AMM_journal)Photo by Acta Materia Medica (@AMM_journal)Photo by Acta Materia Medica (@AMM_journal)Photo by Acta Materia Medica (@AMM_journal)Photo by Acta Materia Medica (@AMM_journal)Photo by Acta Materia Medica (@AMM_journal)Photo by Acta Materia Medica (@AMM_journal)Photo by Acta Materia Medica (@AMM_journal)Photo by Acta Materia Medica (@AMM_journal)
Acta Materia Medica retweeted
This review examines how androgen receptor alterations contribute to CRPC and discusses PROTACs as tools for degrading proteins that sustain disease progression and therapeutic resistance. #CancerBiology #ProstateCancer @harvardmed #AMM #OpenAccess: doi.org/10.15212/AMM-2024-00…
1
1
1
34
Acta Materia Medica retweeted
A randomized trial found that Cs4 improved symptom severity, fatigue, insomnia, respiratory symptoms, and quality of life over 12 weeks in patients with long COVID. #ClinicalTrials #CordycepsSinensis @HKUniversity #AMM #OpenAccess: doi.org/10.15212/AMM-2024-00…
1
1
1
34
Acta Materia Medica retweeted
💊 Not every disease-associated molecular change is a promising drug target. In @DrugTargetRev , our Dr Shi-qi An explores how multiomics, single-cell and spatial technologies can strengthen drug target discovery. 🔗 drugtargetreview.com/home/ho…
1
1
51
Acta Materia Medica retweeted
Be Part of the Future of Pharmacology Join PHARMAUE 2026 – 18th International Conference & Exhibition on Pharmacology, Drug Discovery & Pharmacotherapy. Date: 8–9 December 2026 Venue: Kuala Lumpur, Malaysia & Virtual Register Now: pharmacy.ucgconferences.com/…
1
1
37
Acta Materia Medica retweeted
Join us at these upcoming conferences: - Drug Discovery Chemistry Europe, November 10-12, Barcelona, Spain drugdiscoverychemistry.com/e… - The 43rd Medicinal Chemistry Symposium, November 11-13, Kyoto, Japan k-gakkai.jp/mcs2026/en/en_in… We will be happy to meet you, discuss the latest developments in Drug Discovery, and explore new opportunities for collaboration.
1
2
404
Acta Materia Medica retweeted
🇳🇱 Leiden University — PhD in AI-Driven Drug Discovery 🔥 URGENT | MSCA-Funded | Deadline: November 12, 2026 🏫 University: Leiden University 🔬 Laboratory: Leiden Academic Centre for Drug Research (LACDR) — Computational Drug Discovery Group 📍 Location: Leiden, Netherlands 🆕 Published: October 15, 2026 📖 Research Project: ANA-KIN DC10 — Deep Learning for Kinase Drug Discovery This PhD focuses on developing artificial intelligence models to discover new cancer therapeutics targeting protein kinases. Unlike conventional kinase inhibitors, which primarily target ATP-binding sites, the project investigates alternative regulatory interfaces to improve drug selectivity and overcome resistance. Research Activities: •Develop deep-learning models for kinase inhibitor discovery. •Integrate chemical, structural, and biophysical datasets. •Predict molecular binding and drug-resistance mechanisms. •Design computational approaches for peptide-based therapeutics. •Apply AI models to experimental drug-discovery workflows. •Develop open-source computational tools. The position includes research secondments at two Belgian partner organizations. 💰 Funding Details: ✅ Fully funded through the Horizon Europe MSCA Doctoral Network ANA-KIN. ✅ Four-year salaried PhD position. ✅ Gross monthly salary: €3,204–€4,051. ✅ Additional 8% holiday allowance. ✅ Additional 8.3% year-end allowance. ✅ University pension and employment benefits. ✅ International research secondments and specialist training. Contract Structure: Initial one-year appointment, extendable for the remaining three years after a positive evaluation. 🔍 Application Requirements: •Master’s degree in Computer Science, AI, Computational Chemistry, Bioinformatics, or a related field. •Experience with machine learning and deep learning, preferably PyTorch. •Knowledge of cheminformatics or computational chemistry. •Excellent Python programming skills. •Strong academic English. •Interest in pharmaceutical research. MSCA Eligibility: •Applicants must not already hold a doctoral degree. •Applicants must not have lived, worked, or studied in the Netherlands for more than 12 months during the preceding 36 months, subject to MSCA exceptions. Required Documents: •Motivation letter confirming MSCA eligibility. •Academic CV. •Academic grade list. •Contact details of two referees. 🕒 Application Deadline: November 12, 2026. ⏳ Time Remaining: 4 Days! ⭐ Why Apply? This is an excellent opportunity to combine artificial intelligence with pharmaceutical research. The project offers a competitive Dutch salary, international research experience, and collaboration with academic and industrial partners. 🔗 Official University Application: careers.universiteitleiden.n… #phd #PhD #phdopportunity #phdposition
1
2
72
Acta Materia Medica retweeted
POSTDOCTORAL FELLOWSHIPS IN MEDICINAL CHEMISTRY AT UNIVERSITY OF CAPE TOWN 👇👇👇👇👇👇👇👇 @PostdocPhd @PostdocO
3
1
1
74
Acta Materia Medica retweeted
A response regression model separates viral-load-driven host responses from genuine HTA effects, improving identification of pharmacologically relevant genes. #Virology #Transcriptomics #antiviral #AMM #OpenAccess: doi.org/10.15212/AMM-2025-00…
1
1
1
37
Acta Materia Medica retweeted
Does higher selectivity create higher uncertainty for antibody drugs? A new perspective in #CTSjournal explores how context-dependent pharmacology impacts translation, dose selection, & combination therapy in antibody drug development. Read more: doi.org/10.1111/cts.70556
1
1
3
69
Acta Materia Medica retweeted
The future of drug discovery isn't just about proving a drug works. It's about proving why it can outperform the standard of care. 👉 medvolt.ai #Medvolt #DrugDiscovery #ClinicalTrials #MedGraph #SystemsBiology #AIDrugDiscovery
🤖 Made with AI
1
1
17
Acta Materia Medica retweeted
📊 A bioRxiv preprint outlines a computational pipeline for targeting the ELMO1/DOCK2 complex, suggesting open-access AI tools and public structural data could reprice early drug… 🔗 atlas360.news/en/news/elmo1-… 📩 Subscribe: atlas360.news/en/bulten #health #drugdiscovery #openscience
1
1
1
16
Acta Materia Medica retweeted
This study validates that #Euphorbia humifusa Willd. extract & #Avicularin inhibit #Inflammation & abnormal #Keratinocyte proliferation in #Psoriasis via their modulatory effects on #IL17 signaling, highlighting both therapeutic promise & methodological strength in #NaturalProduct research. #OpenAccess: amm-journal.org/index.php/20…
1
2
1
53
Acta Materia Medica retweeted
This review examines the #Molecular hierarchy and roles of #SKP2 in #CellularHomeostasis, and maps current #therapeutic strategies, aiming to build a #Translational atlas that supports future SKP2-directed interventions for #Cancer and other disorders. @harvardmed #OpenAccess:amm-journal.org/index.php/20…
1
2
68
Acta Materia Medica retweeted
'Discovery of Biased Dual-Agonists of Glucagon-Like Peptide 1 and Glucagon Receptors through Mutation of a Conserved Aspartate' from ACS Medicinal Chemistry Letters is currently free to read as an #ACSEditorsChoice. 📖 Read the article: go.acs.org/enP
1
3
5
1,622
Acta Materia Medica retweeted
Advancing PROTAC therapeutics requires advanced analytics. This Tech Note from @SCIEXnews demonstrates sensitive ARV-110 quantification in rat plasma, critical for pharmacokinetic studies, safety & efficacy evaluation and preclinical development >>> hubs.ly/Q04gMGc10
1
52
Acta Materia Medica retweeted
💊 New paper: DesignMaster — rational PROTAC design with multi-conditional diffusion bioRxiv (Jun 15) | Shi et al. PROTACs degrade proteins instead of just inhibiting them — but designing them is hard. DesignMaster uses diffusion to jointly optimize the linker & warheads under multiple constraints. 📄 biorxiv.org/content/10.64898… #DrugDiscovery #AIxBiology #PROTAC #DiffusionModel
2
89